Enliven Therapeutics (ELVN) Preferred Dividend Payments (2020)

Enliven Therapeutics (ELVN) posted Preferred Dividend Payments of -$42000.0 for Q3 2020, down 200.0% sequentially from $42000.0 in Q2 2020.

Enliven Therapeutics (ELVN) Preferred Dividend Payments (2020) Analysis & Trends

Enliven Therapeutics has reported Preferred Dividend Payments for 1 years, with the latest figure at -$42000.0 in Q3 2020.

Quarterly Preferred Dividend Payments changed N/A year-over-year to -$42000.0 in Q3 2020, while the trailing twelve-month figure through Dec 2020 was $7.9 million (changed N/A YoY) and the FY2021 annual result came in at $7.9 million, up 0.53% from the prior year.
Preferred Dividend Payments eased to -$42000.0 in Q3 2020 per ELVN's latest filing, from $42000.0 in the prior quarter.
Over five years, Preferred Dividend Payments peaked at $7.9 million in Q1 2020 and troughed at -$42000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Pref Dividends (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Enliven Therapeutics	4.31 Bn	3.41 Bn	-	-

Download Data